| |
 |
This is the category page. Below are all of the research programs that are associated with it
- Diabetes Education:
USING A COMMUNITY HEALTH WORKER (PROMOTORA) TO IMPROVE DIABETES SELF-MANAGEMENT TRAINING IN LATINOS: A COMPARATIVE APPROACH (Investigator Initiated Protocol)
(1_20090506_118)
This study is a comparison of two pre-existing Spanish speaking diabetes education programs. Participants already part of the Promotora education courses will be asked to consent to participate in this research study. Participants in the study will be asked to complete additional questionnaires at 6, 12 and 18 months after the completion of the class. A focus group may take place during the 6, 12 and 18 month questionnaire sessions to discuss any issues. Participants may ask to meet privately with the study team at any time.
- Diabetic Patients with Kidney Problems -
CYSTATIN C AS A NEW BIOMARKER FOR THE EARLY DETECTION OF CONTRAST-INDUCED NEPHROPATHY IN THE DIABETIC PATIENT WITH DECOMPENSATED RENAL FUNCTION
(1_20070204_118)
Participants will undergo a series of blood tests including Cystatin C and creatinine, at varying time intervals pre and post contrast. Approximately 20cc of blood will be drawn with each collection. Patients who do not require extended hospitalization following the procedure will be asked to return to the hospital to collect the post-procedure blood samples. Specimens will be collected by LVH nursing staff, in coordination with LVH Research Department.
- TYPE 2 Diabetes
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF 24 WEEKS TREATMENT WITH VILDAGLIPTIN (50mg qd or 100mg qd) VERSUS SITAGLIPTIN (25mg qd) IN PATIENTS WITH TYPE 2 DIABETES AND SEVERE RENAL INSUFFICIENCY (PROTOCOL #CLAF237A23138)
(1_20081005_118)
This is a multi-center randomized research study for patients with Type 2 Diabetes with renal impairment. Participants will receive treatment with vildagliptin or sitagliptin for 24 weeks. Each participant will attend one screening visit were inclusion/exclusion criteria will be assessed. Participants meeting criteria will enter a two week single blind placebo run-in period. During this placebo run-in period a comprehensive baseline medical history will be assessed to provide a relative baseline as this patient population has advanced disease and will continue on their current anti-diabetic diet, exercise and therapy if on treatment at screening. After the run-in period, eligible participants will return for visit 2 and will be randomized to receive one of the two drugs vildagliptin or sitagliptin for 24 weeks. Safety labs will be drawn throughout the study and an electrogardiogram will be performed at visits 1, 5, 6, 7 and 10. Urine studies will be performed at visits 2 and 10.
- TYPE 2 Diabetes -
A PHASE III RANDOMIZED, ACTIVE-COMPARATOR (METFORMIN) CONTROLLED, CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF MK-0431A IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (Protocol #079) (2_20070610_118)
This is a randomized, double-blind, active-comparator controlled study for the treatment of patients with type 2 Diabetes Mellitus (T2DM). Use of FDA approved drugs, combination of sitagliptin/metformin (MK-431A)– starting dose 50/500 mg administered twice daily; then increased to a dose of 50/1000 mg twice daily over 4 Weeks or metformin – starting dose will be 500 mg twice daily; then increased to a dose of 1000 mg twice daily over 4 Weeks. The duration of the study is 45 Weeks which will include 1 Week screening period.
|
|
